Medaxonum

Ceftriaxone, the active ingredient in Medaxonum, is a cephalosporin antibiotic presented as a sterile powder for reconstitution for intramuscular and intravenous use. It provides broad‑spectrum bactericidal activity for serious infections such as pneumonia, meningitis and gonorrhea in adult and pediatric patients.

GNH USA supplies Medaxonum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ceftriaxone is a broad‑spectrum cephalosporin used to treat bacterial infections affecting various organ systems.

- Community‑acquired pneumonia: achieves rapid bacterial clearance and clinical improvement in pulmonary infection. - Meningitis: penetrates the cerebrospinal fluid to eradicate the causative pathogens. - Gonorrhea: provides effective single‑dose therapy for uncomplicated infection. - Urinary tract infections: resolves uropathogenic bacterial growth. - Skin and soft‑tissue infections: eliminates common Gram‑positive and Gram‑negative organisms.

Ceftriaxone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Injection site pain: discomfort at the site of intramuscular or intravenous administration. - Diarrhea: mild to moderate loose stools. - Nausea: transient feeling of queasiness. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Transient increase in bilirubin: mild hyperbilirubinemia without clinical significance.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Stevens‑Johnson syndrome: rare severe mucocutaneous eruption. - Clostridioides difficile‑associated diarrhea: severe colitis following disruption of gut flora. - Hemolytic anemia: immune‑mediated destruction of red blood cells. - Severe hepatic dysfunction: marked liver injury. - Renal impairment: acute kidney injury, especially with concomitant nephrotoxins.

Ceftriaxone requires careful consideration of patient‑specific factors before use.

- Renal impairment: monitor renal function and adjust dosing as needed. - Hepatic dysfunction: observe liver enzyme levels during therapy. - Neonates and infants: risk of biliary sludging; use with caution. - Allergy to beta‑lactams: avoid in patients with known hypersensitivity. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Ceftriaxone can interact with several medicines, influencing safety or efficacy.

Major Interactions (Avoid): - Calcium‑containing solutions: may precipitate when mixed intravenously, causing embolism. - Warfarin: can potentiate anticoagulant effect, increasing bleeding risk. - Aminoglycosides: concurrent use may heighten nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance of ceftriaxone. - Probenecid: can increase serum ceftriaxone concentrations, requiring dose adjustment.